236750-65-5

Basic information

• Product Name: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile
• Synonyms: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile;Erlotinib interMediate;2-nitro-4,5-bis(2-Methoxyethoxy)benzonitrile;4,5-Di(2-methoxyethoxy)-2-nitrobenzonitrile;Erlotinib Impurity 19;Erlotinib Impurity 32;Erlotinib Impurity W;Erlotinib intermediates
• CAS NO: 236750-65-5
• Molecular Formula: C₁₃H₁₆N₂O₆
• Molecular Weight: 296
• EINECS: 1308068-626-2
• Mol File: 236750-65-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 459.3oC at 760 mmHg
• Flash Point: 231.6oC
• Appearance: /
• Density: 1.26g/cm3
• Vapor Pressure: 1.28E-08mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(236750-65-5)
• EPA Substance Registry System: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(236750-65-5)

Safety Data

• Hazardous Substances Data: 236750-65-5(Hazardous Substances Data)

Usage

Description

4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile is an organic compound that is identified as an impurity in Erlotinib (E625008), a targeted drug used in the treatment of non-small cell lung cancer. It is characterized by its molecular structure that includes a nitro group and a cyano group attached to a benzene ring, with two methoxyethoxy substituents at the 4,5-positions.

Uses

Used in Pharmaceutical Industry:
4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile is used as an impurity in the production of Erlotinib, an EGFR small tyrosine kinase inhibitor. It is significant in the pharmaceutical industry due to its association with a drug that has a substantial effect on tumor growth inhibition and animal survival in the context of non-small cell lung cancer treatment.
The compound's presence as an impurity in Erlotinib highlights the importance of quality control and purification processes in the pharmaceutical manufacturing sector. Ensuring the purity and safety of drugs is crucial for their efficacy and the well-being of patients undergoing treatment.

InChI:InChI=1/C13H16N2O6/c1-18-3-5-20-12-7-10(9-14)11(15(16)17)8-13(12)21-6-4-19-2/h7-8H,3-6H2,1-2H3

Upstream product

• 121-33-5 vanillin 
• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 17345-61-8 3,4-dihydroxybenzonitrile 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 1418289-91-4 3,4-bis(2-methoxyethoxy)-benzamide 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 80407-64-3 3,4-bis(2-methoxyethoxy)benzaldehyde 
• 1006377-63-4 C₁₃H₁₉NO₅ 
• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 

Downstream Products

• 179688-29-0 6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 
• 183319-69-9 erlotinib hydrochloride 
• 950596-59-5 N′-[2-cyano-4,5-{bis(2-methoxyethoxy)phenyl}]-N,N-dimethylformamidine 
• 183321-74-6 erlotinib 
• 1172625-04-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzamide 
• 236750-62-2 2-amino-4,5-bis[(2-methoxy)ethoxy]benzamide 
• 950596-58-4 2-amino-4,5-bis-(2-methoxyethoxy)-benzonitrile 

Relevant articles and documents

Preparation method of erlotinib hydrochloride intermediate

The invention provides a preparation method of an erlotinib hydrochloride intermediate. The preparation method comprises following steps: removing the methyl of vanillin, performing esterification, converting an aldehyde group into a nitrile group, and carrying out nitration, reduction, hydrolysis, and ring forming reactions. The reaction route is represented in the description. The technology isreasonable, the operation is simple, the cost is low, and the reaction yield is high.

Method for preparing compound

The invention provides a method for preparing a compound as shown in a formula I which is described in the specification. The method comprises a step of contacting a compound as shown in a formula III which is described in the specification or a derivative thereof with a compound as shown in a formula II which is described in the specification so as to obtain the compound as shown in the formula I. In the formulas, R1 and R2 are hydrogen, alkoxy groups or heteroaromatic rings, preferably alkoxy groups; and R is hydrogen, an alkyl group, a phenyl group, a substituted phenyl group or a naphthyl group. The compound as shown in the formula I is a tinib drug intermediate 6,7-disubstituted quinazolinone. According to the method provided in embodiments in the invention, aldoketones are used as cyclization raw materials in replacement of carboxylic acids for preparation of tinib drug intermediate, and since the aldoketones are not corrosive, the method has low requirements on reaction equipment and is more favorable for industrial production.

Compounds for use in inhibiting HIV capsid assembly

The present invention relates to a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, the compound comprising the core structure wherein E is CR7or S, and wherein f is 0 or 1, and wherein in case E is S, f is 0, and wherein the core structure is at least substituted in 2 and 4 position, and wherein the residue R6 and R7, are, independently of each other, selected from the group consisting of -H, -D, -alkyl, alkoxy, alkenyl, alkynyl, halides, -NO2, - OH, - NH2, -NHR4#, -CN, -S(O)R4#, -SO2R4#, -P(O)R4#R5#, -P(O)(OR4#)R5#, - P(O)(OR4#)(OR5#), -C(O)NR4#R5#, -C(O)SR4#, -C(O)R4#, -C(O)O-R4#, alkoxy and glycol chains; and wherein R6 may optionally form a cyclic residue, with a further substituent present 5 or 6 position, and wherein R4# and R5# are, independently of each other, selected from the group consisting of -H, -alkyl, -alkenyl, - heterocycloalkyl, aryl and heteroaryl.